• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Real-world data study of BRAF mutant metastatic colorectal cancer patients across the Greater Manchester region prior to BEACON trial results

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Realworld data.pdf
    Size:
    83.11Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Cairns, R.
    Brown, M.
    Al-Ani, M.
    Burghel, G.
    Mullamitha, Saifee A
    Marti-Marti, Francisca
    Hasan, Jurjees
    Kamposioras, Konstantinos
    Alchawaf, A.
    Lavin, V.
    Alam, Nooreen
    Arthur, C.
    Misra, Vivek
    Nasralla, M.
    Saunders, Mark P
    Wallace, A.
    Braun, Michael S
    Barriuso, Jorge
    Show allShow less
    Affiliation
    University of Manchester / The Christie NHS Foundation Trust, Manchester
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background BRAF mutations are known to impact both prognosis and anti-EGFR response in metastatic colorectal cancer (mCRC). Methods All consecutive pts (n=80) with BRAF mutation from 2016 to 2018 were included in this real-world data (RWD) study. Data were obtained from electronic patient records. Survival univariate analysis (UVA) was performed with Kaplan-Meier curves and log-rank test. Multivariable survival analysis (MVA) was performed by Cox regression. Results Median age for the 80 pts was 68y (range 32 to 82). Median follow up was 10.2 months (ms). Females 36 pts (45%) and males 44 (55%). Anatomically, 42.5% were ascending colon, 13.7% transverse, 21.9% sigmoid and 17.8% rectum; in summary, right colon tumours accounted for 51.5%. Seventy (87.2%) pts had BRAF V600E mutation. KRAS mutation was present in 7 cases (8.8%), 4 (5%) were co-expressed with BRAF V600E mutations. Sixteen (20%) had a PIK3CA mutation. The most common first-line chemotherapy backbone was FOLFOX (41.5%), followed by FOLFIRI (40%). Only 12 pts (15%) received anti-EGFR antibodies, 9 of them with BRAF V600E mutations. The median variant allele frequency for BRAF variants was 22%, ranging from 2 to 56%. Responses by RECIST criteria to first line were, complete response (CR) in 4 (6.5%) out of 61 evaluable patients, partial response (PR) in 12 (19.7%), stable disease (SD) in 16 (26.2%) and progressive disease (PD) in 29 (47.6%). Overall survival (OS) for the full cohort was 11.4 ms 95%CI (9.2-13.7). First-line progression-free survival (PFS) for the full cohort was 5.3 ms 95%CI (3.7-6.9). In the UVA for OS, sidedness was statistically significant (p=0.048) with right-sided tumours having a median OS of 9.7 ms 95%CI (5.6-13.7) vs left-sided 13.6 ms 95%CI (5.4-21.8). However, when the analysis was stratified by BRAF mutation, the difference was not statistically significant (p=0.204); a trend was observed for the non-V600E (p=0.058). No differences in OS were found regarding the chemotherapy backbone or anti-EGFR antibodies. In the first line, responders had a better OS of 14.8 ms (95%CI 0.0-30.2) vs the OS of non-responders which was 9.2 ms (95%CI 6.9-11.4, p=0.005). There were no differences regarding baseline ECOG. In the UVA for PFS, responders had a better PFS 9.7 ms (95%CI 5.0-14.3) vs non-responders PFS 3.2 (95%CI 2.5-3.9, p=0.001) and it was the only significant variable. In the MVA analyses for OS, response by RECIST remained as an independent prognostic factor when adjusted for BRAF variant, gender, EGOG and sidedness (HR: 0.6 95%CI 0.4-0.8 with p=0.003). In the MVA analyses for PFS, response by RECIST remained significant when corrected for BRAF variant, gender ECOG and sidedness (HR: 0.6 95%CI 0.4-0.7, p< 0.001). Conclusion In our RWD study, response to treatment was the main independent factor associated with PFS and OS for the first line of treatment. This is in keeping with the utility of chemotherapy triplets in this subgroup.
    Citation
    Cairns R, Brown M, Al-Ani M, Burghel G, Mullamitha S, Marti FM, et al. P-332 Real-world data study of BRAF mutant metastatic colorectal cancer patients across the Greater Manchester region prior to BEACON trial results. Annals of Oncology. 2020;31:S197.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623320
    DOI
    10.1016/j.annonc.2020.04.414
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.04.414
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.04.414
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.